Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799632 | 0.91 | ICMT (0.35) | ICMTTDP1KDM4EALDH1A1CAPN1 | |
| SCHEMBL22800166 | 0.91 | L3MBTL1 (0.36) | ICMTTDP1KDM4EALDH1A1CAPN1 | |
| SCHEMBL22800223 | 0.89 | ICMT (0.36) | ICMTTDP1KDM4EALDH1A1CAPN1 | |
| SCHEMBL22800187 | 0.77 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL22799717 | 0.75 | CAPN1 (0.47) | KDM4ECAPN1HDAC3HDAC1MEN1 | |
| SCHEMBL22799711 | 0.75 | CAPN1 (0.47) | KDM4EALDH1A1CAPN1HDAC3HDAC1 | |
| SCHEMBL22800074 | 0.73 | ICMT (0.35) | ICMTTDP1KDM4ECAPN1MEN1 | |
| SCHEMBL22800185 | 0.73 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL22800227 | 0.72 | CYP4F2 (0.39) | KDM4EALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL22799768 | 0.72 | CYP4F2 (0.39) | KDM4EALDH1A1MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | ICMT 4672/4885TDP1 1499/4885KDM4E 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.